Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma

Phase 1BEA-17Positive

AI Analysis

Summary

Beactica Therapeutics initiated IND-enabling studies for BEA-17, a first-in-class oral degrader of LSD1 and CoREST, for glioblastoma treatment. The program represents early-stage development progress toward potential clinical candidacy.

Outcome Details

IND-enabling studies initiated for first-in-class LSD1-CoREST degrader

Importance:5/10

Sentiment:

0.60

IND-enabling studiesfirst-in-classglioblastomaepigenetic regulatordegraderprecision medicine

Related Companies

$DTIL $SHWZ $SOBI.ST $TRAX

Read the original article

Published by PR Newswire Biotech on September 22, 2026 6:21 AM

Read Original